We Are Crinetics

Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with
rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately
about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives
in significant ways.


A Phase 2, Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

Presented by:

Aman Chauhan, M.D., study co-author
Director of NET Theranostics UK Markey Cancer CenterUniversity of Kentucky Healthcare
Friday, October 28, 5:15-7:00PM in The Poster Hall

200113amanchauhan134 4 1 uai


Please fill out the information below and our medical affairs team will reach out to you about Crinetics and our Phase 2 and future Phase 3 studies with paltusotine for the treatment of carcinoid syndrome.